Everything’s Bigger in Texas (Pleading Standard Edition)

Key Takeaways

• Texas pleading standard lower than federal 12(b)(6).
• Epic allegedly waived tying and pricing arguments.
• State claims Epic is covered entity under Texas law.
• Motion to dismiss likely denied on antitrust counts.
• Discovery phase will determine broader compliance liabilities.

Summary

The Texas Attorney General filed an opposition to Epic’s motion to dismiss, arguing that Epic cannot import federal summary‑judgment standards into a state‑court pleading under Texas Rule 91a. The brief emphasizes that Epic’s reliance on a patchwork of federal cases fails to meet settled Texas law, and that Epic waived several antitrust theories such as tying and retaliatory pricing. Texas also asserts that Epic qualifies as a covered entity under a broad state health‑code definition, raising compliance questions. Analysts expect the motion to be denied, pushing the case into discovery.

Pulse Analysis

Texas’s opposition to Epic’s dismissal hinges on Rule 91a, which requires only a plausible factual basis rather than the stricter federal 12(b)(6) test. By keeping the case in state court, Texas forces Epic to defend its antitrust allegations under a more forgiving pleading regime, while simultaneously demanding reliance on settled Texas statutes and precedent. This procedural maneuver underscores the strategic advantage states can wield when federal defendants choose local venues, potentially reshaping litigation tactics for nationwide tech firms.

The health‑and‑safety code argument widens the definition of a "covered entity" to include any party with constructive knowledge of protected health information. Texas courts may deem Epic’s EHR platform a covered entity despite the company’s claim it does not store patient data, because the software’s architecture effectively “possesses” the information. This expansive reading threatens not only Epic but all electronic health‑record vendors, compelling them to embed compliance controls directly into their code rather than relying on client‑side configurations, thereby increasing development costs and legal exposure.

If the motion to dismiss is rejected, the case will move into discovery, where the depth of Epic’s market power and compliance practices will be scrutinized. A robust discovery phase could expose systemic anticompetitive behavior and reinforce state‑level enforcement of health‑privacy statutes. For the broader market, the outcome may signal heightened regulatory vigilance, prompting health‑tech companies to reassess product roadmaps, pricing strategies, and data‑handling architectures to mitigate future litigation risk.